BACKGROUND: New automated and ultrasensitive assays are becoming available to monitor HIV-1 plasma viral load, which is an essential marker for the clinical follow-up. OBJECTIVES: To evaluate the performances of the VERSANT HIV-1 RNA 1.0 (kPCR) automated assay in a clinical laboratory setting. STUDY DESIGN: Frozen plasma samples from various HIV-1 subtypes, previously analysed with the VERSANT HIV-1 RNA 3.0 (bDNA) in clinical routine, were retested with the new VERSANT kPCR assay. A comparison was also done with two other commercial assays (NucliSens EasyQ HIV-1 and Abbott real time HIV-1). RESULTS: We observed a good correlation between the viral load measurements obtained with the kPCR assay and the other techniques. Nevertheless, in terms of absolute quantification, we observed discrepancies of more than 0.5 log cop/ml plasma with 36%, 35% and 0% of the samples respectively with NucliSens EasyQ, VERSANT bDNA 3.0 and Abbott real time. No HIV-1 negative sample was amplified by the kPCR. Tenfold dilutions of samples from HIV-1 subtypes A-D, F-H, K, CRF01, CRF02 and CRF06 were analysed to evaluate the kPCR efficiency: the amplification had an efficiency close to the maximum of 2 for each of the subtypes tested. CONCLUSIONS: The VERSANT HIV-1 RNA 1.0 assay (kPCR) is suitable for use in a clinical setting with various HIV-1 subtypes. The plasma viral load quantifications obtained with the kPCR assay were close to those obtained with the Abbott real time HIV-1 assay.
BACKGROUND: New automated and ultrasensitive assays are becoming available to monitor HIV-1 plasma viral load, which is an essential marker for the clinical follow-up. OBJECTIVES: To evaluate the performances of the VERSANT HIV-1 RNA 1.0 (kPCR) automated assay in a clinical laboratory setting. STUDY DESIGN: Frozen plasma samples from various HIV-1 subtypes, previously analysed with the VERSANT HIV-1 RNA 3.0 (bDNA) in clinical routine, were retested with the new VERSANT kPCR assay. A comparison was also done with two other commercial assays (NucliSens EasyQ HIV-1 and Abbott real time HIV-1). RESULTS: We observed a good correlation between the viral load measurements obtained with the kPCR assay and the other techniques. Nevertheless, in terms of absolute quantification, we observed discrepancies of more than 0.5 log cop/ml plasma with 36%, 35% and 0% of the samples respectively with NucliSens EasyQ, VERSANT bDNA 3.0 and Abbott real time. No HIV-1 negative sample was amplified by the kPCR. Tenfold dilutions of samples from HIV-1 subtypes A-D, F-H, K, CRF01, CRF02 and CRF06 were analysed to evaluate the kPCR efficiency: the amplification had an efficiency close to the maximum of 2 for each of the subtypes tested. CONCLUSIONS: The VERSANT HIV-1 RNA 1.0 assay (kPCR) is suitable for use in a clinical setting with various HIV-1 subtypes. The plasma viral load quantifications obtained with the kPCR assay were close to those obtained with the Abbott real time HIV-1 assay.
Authors: Vicki L Greengrass; Megan M Plate; Pauline M Steele; Justin T Denholm; Catherine L Cherry; Lisa M Morris; Anna Hearps; Suzanne M Crowe Journal: J Clin Microbiol Date: 2009-07-15 Impact factor: 5.948
Authors: Kimberly A Sollis; Pieter W Smit; Susan Fiscus; Nathan Ford; Marco Vitoria; Shaffiq Essajee; David Barnett; Ben Cheng; Suzanne M Crowe; Thomas Denny; Alan Landay; Wendy Stevens; Vincent Habiyambere; Jos Perrins; Rosanna W Peeling Journal: PLoS One Date: 2014-02-18 Impact factor: 3.240